Stay updated on Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial page.

Latest updates to the Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial page
- Check5 days agoChange DetectedA sitewide notice about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” appears above the page, and the footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe site’s footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check26 days agoChange DetectedThe page previously displayed a 403 Forbidden error, and now shows the full study record for the trial, including the overview, design, primary and secondary outcomes, eligibility criteria, and contacts/locations.SummaryDifference100%

- Check33 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a simple error screen and a Home link. Users cannot view the study details or related information on this page.SummaryDifference17%

- Check40 days agoChange DetectedA new revision tag was added (v3.7.0) and several related-topic entries were removed, indicating housekeeping updates to the page's metadata and topics.SummaryDifference0.1%

- Check54 days agoChange DetectedLung cancer is added as a MeSH term and a Related topics section now includes a MedlinePlus Genetics link. The revision label was updated to v3.6.6 from v3.6.5.SummaryDifference0.1%

Stay in the know with updates to Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial page.